A clinical formulation indicated for Oncology Support. This therapy assists with the inhibition of abnormal cell proliferation to promote stable physiological status.
Utilized to manage cancer cell growth and address severe autoimmune responses to alleviate symptoms and support long-term disease remission in high-risk clinical scenarios.
Mechanism of Action
Cyclophosphamide attaches alkyl groups to DNA strands, which cross-links the DNA and prevents cells from dividing. It targets rapidly dividing cells like cancer and immune cells, disrupting their reproduction.
Route of Administration
Oral
Onset Time
Steady state in 2 days
Duration
Variable; 8–12 hours
Contraindications
Severely suppressed bone marrow, Active severe infection, Hypersensitivity to cyclophosphamide, Pregnancy
Severe Adverse Events
Hemorrhagic cystitis (bladder bleeding), Severe bone marrow suppression, Secondary cancers, Severe lung toxicity, Cardiac failure, Infertility
Common Side Effects
Nausea, Temporary hair loss
Uncommon Side Effects
Vomiting, Loss of appetite, Mouth sores, Diarrhea, Anemia, Changes in menstrual cycle
Drug Interactions
Allopurinol, Warfarin, Phenobarbital, Rifampin, Digoxin, Live vaccines
Pregnancy Safety Warnings
Contraindicated; can cause severe birth defects.
Age Restrictions
Individualized dose for children based on surface area.
Storage Guidelines
Store at room temperature protected from moisture.
Information for Cyclophosphamide is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
